NCT04772612 is a Phase 1 clinical trial of sitravatinib in Hepatic Impairment, sponsored by Mirati Therapeutics Inc..

Who is sponsoring NCT04772612?

NCT04772612 is sponsored by Mirati Therapeutics Inc..

What drugs are being tested in NCT04772612?

Interventions in NCT04772612: sitravatinib.

What condition does NCT04772612 study?

NCT04772612 studies Hepatic Impairment.

Is NCT04772612 still recruiting?

NCT04772612 is currently completed. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT04772612

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Completed Phase 1 Last updated 23 October 2023

What this trial tests

Phase 1 trial testing sitravatinib in Hepatic Impairment in 30 participants. Completed in 13 April 2023.

Timeline

12 March 2021

Primary endpoint
13 July 2022

13 April 2023

Quick facts

Lead sponsor	Mirati Therapeutics Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	12 March 2021
Primary completion	13 July 2022
Estimated completion	13 April 2023
Sites	5 locations across United States

Drugs / interventions tested

sitravatinib (sitravatinib) — full drug profile →

Conditions studied

Hepatic Impairment — all drugs for Hepatic Impairment →

Sponsor

Mirati Therapeutics Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Hepatic Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy.
Mikolajczyk A, Mitula F, Popiel D, Kaminska B, et al · · 2022 · cited 13× · PMID 35626092 · DOI 10.3390/cancers14102488
Probable Cerebral Amyloid Angiopathy-Related Inflammation Associated With Sitravatinib: A Case Report.
Ray C, Dionne K. · · 2022 · cited 3× · PMID 35747887 · DOI 10.1212/cpj.0000000000001162

Verify or expand the search:

Other trials of sitravatinib

Trials testing the same drug.

NCT04800614 — A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib · Phase 1 · completed

Other recruiting trials for Hepatic Impairment

Currently open trials in the same condition.

NCT07269301 — A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function · Phase 1 · recruiting
NCT07219550 — A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) · Phase 1 · recruiting
NCT07144111 — A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib · Phase 1 · recruiting
NCT07023354 — A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems · Phase 1 · recruiting
NCT06985615 — A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement · Phase 1 · recruiting

Other Mirati Therapeutics Inc. trials

Trials by the same sponsor.

NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT06875310 — A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participan · Phase 3 · recruiting
NCT06801418 — Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets · Phase 1 · completed
NCT05853575 — Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) · Phase 2 · active not recruiting
NCT05840510 — Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04772612 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mirati Therapeutics Inc.
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04772612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing